louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06179862: Effects of Hamstring Shortness on Jump Performance in Young Basketball Players Impact
Official title: Effects of Hamstring Shortness on Jump Performance in Young Basketball Players Impact
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hamstring Injury
Keywords: basketball
shortness
Lead sponsor: Istanbul Medipol University Hospital
Sponsor class: OTHER
First posted: 2023-12-22
Enrollment: 84
Sex: MALE
Minimum age (years): 10
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Amateur basketball players will be included in the study

Brief summary: In the realm of sports performance, particularly in disciplines demanding explosive lower-body strength and agility, such as basketball, an athlete's ability to execute powerful and high-reaching jumps plays a pivotal role. Optimal lower-extremity flexibility, particularly in the hamstrings, is crucial for achieving maximum vertical jump height. Hamstring shortness, characterized by limited flexibility and reduced muscle extensibility, is frequently observed among athletes and has been linked to compromised jump performance.

Detailed description: Young basketball players, in their developmental stages, often face the challenge of balancing strength, flexibility, and functional movement. Hamstring tightness is a prevalent issue among this demographic, potentially influencing their ability to generate adequate power during jumps. The impact of hamstring shortness on jump performance is multifaceted, affecting the force production, range of motion, and efficiency of movement crucial for executing explosive jumps

Eligibility criteria: Inclusion criteria

* To be between 10-16 years old
* Being a licensed basketball player
* Playing in the Istanbul Local Basketball League run by the Turkish Basketball Federation
* Sit-to-Face test 30 cm and below Goniometric measurement less than 80 degrees in active straight leg raising test, Exclusion criteria
* Having played one match in the 48 hours prior to the evaluation
* Having a lower extremity injury.
* Participants of both genders will be included in the study.

Primary outcomes:
measure: Goniometric Measurement
timeFrame: day 1
measure: sit and reach
timeFrame: day 1
measure: Y Balance Test
timeFrame: day 1
measure: Popliteal Angle Measurement (Holt Method)
timeFrame: day 1
measure: vertical jump Height
timeFrame: day 1
measure: The duration of the jump (milliseconds)
timeFrame: day 1
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Bahçehir University
Study officials:
References:
Clinical trial NCT05012462: Clinical Evaluation of the CM-1500 During Apheresis Blood Donation
Official title: Clinical Evaluation of the CM-1500 During Apheresis Blood Donation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Fluid Loss
Lead sponsor: Zynex Monitoring Solutions
Sponsor class: INDUSTRY
First posted: 2021-08-19
Enrollment: 77
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The study is a prospective, single-arm, non-randomized, non-blinded, non-controlled, non-significant risk, single center study enrolling up to 200 healthy adult subjects consented to undergo an apheresis donation procedure. Subjects will be connected to the Zynex Cardiac Monitor, Model 1500 (CM-1500) to characterize changes in the relative index during an apheresis donation procedure.


Eligibility criteria: Inclusion Criteria:

* Ability to provide written informed consent
* Ability and willingness to comply with the study procedures and duration requirements
* 18 years of age or older
* Consented to undergo an apheresis procedure with an automated blood component device

Exclusion Criteria:

* Females who are pregnant or breastfeeding
* Undergone an amputation of the left upper extremity
* Diagnosed with dextrocardia
* Subjects who have a pacemaker

Primary outcomes:
measure: Characterize Changes in the Relative Index During an Apheresis Procedure
timeFrame: Duration of apheresis procedure (e.g., 2 - 3hrs)
Secondary outcomes:
Other outcomes:
Locations:
city: Denver
country: United States
facility: Vitalant Blood Donation
state: Colorado
Study officials:
affiliation: Vitalant Blood Donation
name: Samantha Mack, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04927962: Psycho-social Impact of Amelogenesis and Dentinogenesis Imperfecta
Official title: Psycho-social Impact of Amelogenesis and Dentinogenesis Imperfecta in Young People
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Dentinogenesis Imperfecta
Amelogenesis Imperfecta
Keywords: Amelogenesis imperfecta
Dentinogenesis imperfecta
Bullying
Oral health related quality of life
Dental anxiety
Lead sponsor: University Hospital, Toulouse
Sponsor class: OTHER
First posted: 2021-06-16
Enrollment: 87
Sex: ALL
Minimum age (years): 10
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients having a non-syndromic amelogenesis imperfecta or dentinogenesis imperfecta and consulting for a care or follow-up consultation.

Brief summary: The purpose of this research is to study the impact of dentinogenesis (DI) and amelogenesis (AI) imperfecta on oral quality of life, exposure to bullying and dental anxiety in a population of adolescents. WThe present study will use validated scales to evaluate the impact of bullying on the oral quality of live of youth aged 10 to 18 years, with non-syndromic DI or AI treated in seven national competence or reference centers in rare oral diseases.


Eligibility criteria: Inclusion Criteria:

* be between 10 and 18 years of age,
* consult for a care or follow-up consultation
* having a non-syndromic amelogenesis imperfecta or dentinogenesis imperfecta
* having access to a cell phone and/or tablet and/or personal or family computer
* covered by the social security of one of his parents
* understand French and one of whose parents (or legal representative) understands French
* have declared his or her non-opposition and one of whose parents (or legal representative) has declared his or her non-opposition to participate in the study.

Exclusion Criteria:

* Child presenting for diagnostic consultation and child who cannot read or whose 2 parents (legal representatives) cannot read

Primary outcomes:
measure: Child Oral Health Impact Profile (COHIP)
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Bordeaux
country: France
facility: CHU de Bordeaux
city: Lyon
country: France
facility: Hospices Civils de Lyon
city: Marseille
country: France
facility: AP-HM
city: Nantes
country: France
facility: CHU de Nantes
city: Paris
country: France
facility: AP-HP
city: Strasbourg
country: France
facility: Hôpitaux Universitaires de Strasbourg
city: Toulouse
country: France
facility: University hospital of Toulouse
Study officials:
affiliation: University hospital of Toulouse
name: Frédéric VAYSSE
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00598962: Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease
Official title: Open, Noncomparative Trial of Multidrug Regimens Containing Azithromycin and Rifabutin Administered Three Times Per Week for the Treatment of M. Avium Complex (MAC) Lung Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Mycobacterium Avium Complex
Keywords: MAC
Lead sponsor: The University of Texas Health Science Center at Tyler
Sponsor class: OTHER
Collaborators: name: Pfizer
First posted: 2008-01-23
Enrollment: 58
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To determine the safety and efficacy of azithromycin, rifabutin and ethambutol given three times weekly in the treatment of lung infection with M. avium complex(MAC)

Detailed description: Azithromycin given 3 times weekly along with rifampin/rifabutin and ethambutol for treatment of MAC

Eligibility criteria: Inclusion Criteria:

* Meet American Thoracic Society criteria for nontuberculous lung disease: two or more AFB smear positive, culture positive sputums or bronchoscopic samples and/or two or more AFB smear negative respiratory samples with moderate to heavy growth (2+-4+); abnormal CXR consistent with M. avium lung disease; abnormal CXR consistent with M. avium lung disease; absence of other lung pathogens (except for the coexistence of M. abscessus).
* Age 18 and older
* Pretreatment isolate of M. avium complex available for MIC determination
* Baseline laboratory and clinical testing for baseline CBC, Chemistry (including liver enzymes), hearing test, visual acuity and color discrimination
* Available for long term followup

Exclusion Criteria:

* History of macrolide or rifamycins allergy
* Laboratory evidence of mycobacterial resistance to azithromycin
* Children less than 18 years of age
* If a menstruating female, not pregnant and on adequate birth control
* HIV+ or at risk

Primary outcomes:
measure: Clinical and microbiological outcomes such as clinical symptoms and laboratory cultures
timeFrame: 6 months
Secondary outcomes:
measure: Microbiological cultures
timeFrame: 1yr
Other outcomes:
Locations:
city: Tyler
country: United States
facility: The University of Texas Health Science Center at Tyler
state: Texas
Study officials:
affiliation: The University of Texas Health Science Center at Tyler
name: Richard J Wallace Jr., M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00619762: Immediate Postmastectomy Breast Reconstruction (Strattice Breast)
Official title: A Multicenter, Prospective, Open-Label Study to Assess the Clinical Outcomes of LTM Use in Two-Stage Breast Reconstruction Immediately Post Mastectomy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Cancer
Keywords: Breast reconstruction
Lead sponsor: LifeCell
Sponsor class: INDUSTRY
First posted: 2008-02-21
Enrollment: 17
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: women undergoing two-stage immediate breast reconstruction following a skin sparing mastectomy will be recruited from up to ten (10) participating centers

Brief summary: This prospective, multicenter, open-label study will assess the clinical outcomes of the LTM product in three planned analyses. The primary objective of this study is to prospectively assess the clinical outcomes associated with the use of LTM in two-stage (expander then permanent implant) immediate post-mastectomy breast reconstruction.

Detailed description: nothing to add

Eligibility criteria: Inclusion Criteria:

* A candidate for immediate, two-stage breast reconstruction using LTM following a skin sparing mastectomy
* An ASA Physical Status Classification5 of 1 or 2 (see App I)
* Estimated life expectancy \> 1 year

Exclusion Criteria:

* Clinically significant systemic disease
* Received inductive chemo-therapy within 2 months prior to mastectomy or radiation therapy to the region at any time
* Predicted excised breast mass of \>750 gms
* Co-morbid factors which predispose to postoperative infection, such as insulin dependent diabetes, smoking, chronic steroid use, malnourishment, or co-existent infection
* Need for tissue flap in addition to expander
* History of alcohol abuse, illicit drug use, significant mental illness, physical dependence to any opioid, or drug abuse or addiction
* Enrollment or plans to enroll in another clinical trial during this study that would affect the patient's safety or results of this trial
* Any of the conditions identified within the labeled contraindications, i.e. sensitivity to porcine derived products or polysorbate

Primary outcomes:
measure: Histology Sample Evaluations Assessing Incorporation of StratticeTM Reconstructive Tissue Matrix
timeFrame: At the time of expander/implant exchange (Stage II),
Secondary outcomes:
measure: Severity of Local Inflammation at and Around the Surgical Site
timeFrame: Postoperative Day 7, 14, 21, 30 days
Other outcomes:
Locations:
city: Washington
country: United States
state: District of Columbia
city: Chicago
country: United States
state: Illinois
city: Great Neck
country: United States
state: New York
city: Willow Grove
country: United States
state: Pennsylvania
city: McLean
country: United States
state: Virginia
Study officials:
affiliation: LifeCell
name: Michael Franz, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04690062: BEOVU in the Treatment of Dystrophy-related Macular Neovascular Degeneration
Official title: Brolucizumab-dbll (BEOVU®) Intravitreal Injection in the Treatment of Dystrophy-related Macular Neovascular Degeneration
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Dystrophy, Retinal
Keywords: macular degeneration
BEOVU
RETINAL DYSTROPHY
Lead sponsor: Benha University
Sponsor class: OTHER
First posted: 2020-12-30
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Dystrophy-Related macular neovascularization degeneration occur is a vision threatening condition.The investigators evaluate the efficacy of BEOVU intravitreal treatment.

Detailed description: Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done.

Procedure included intravitreal injection of Brolucizumab (BEOVU®, Genen-tech, South Francisco, CA)

Eligibility criteria: Inclusion Criteria:

* Dystrophy-Related macular neovascularization degeneration

Exclusion Criteria:

* age related macular degeneration , other causes of macular neovascularization degeneration

Primary outcomes:
measure: Best corrected visual acuity (BCVA)
timeFrame: 12 months
Secondary outcomes:
measure: optical coherence tomography (OCT) foveal thickness
timeFrame: 12 months
Other outcomes:
Locations:
city: Abu Dhabi
country: United Arab Emirates
facility: INMC
Study officials:
affiliation: Benha university faculty of medicine , INMC
name: Tarek Elhamaky, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01850862: Progressive Collective-exercise Program on the Knee Osteoarthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Knee Osteoarthritis
Lead sponsor: Universidade Federal do Rio Grande do Norte
Sponsor class: OTHER
First posted: 2013-05-10
Enrollment: 30
Sex: ALL
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators hypothesized that an eight-week collective group exercise program would improve pain, quality of life and functional capacity in patients with knee osteoarthritis (KOA) compared with those receiving no exercise intervention.


Eligibility criteria: Inclusion Criteria:

* symptomatic and moderate to severe medical diagnostic of KOA.
* Subjects with normal cognitive functions and no restriction to perform physical activities were recruited from the hospital's KOA database and eligible to participate if they had presented: Lequesne questionnaire criteria (5 - 13.5), knee pain score between 3 and 7 (on a 0 -10 Visual Analogue Scale), stable doses of non-steroidal anti-inflammatory drugs (NSAIDs) and no regular physical exercise or use of canes in the months prior to the study.

Exclusion Criteria:

* Symptomatic heart disease; symptomatic disease of the lower limbs (other than KOA); symptomatic lung disease; severe systemic disease; severe psychiatric illness; regular physical exercise (three or more times per week for at least 3 months); drug injection in the knee in the previous 3 months; physiotherapy on the lower limbs in the previous 3 months and absence in two consecutive training sessions or three nonconsecutive sessions

Primary outcomes:
measure: Pain
timeFrame: Eight weeks
Secondary outcomes:
measure: quality of life
timeFrame: Eight weeks
Other outcomes:
measure: functional capacity
timeFrame: Eight weeks
Locations:
city: Natal
country: Brazil
facility: Federal University of Rio Grande do Norte
state: RN
Study officials:
affiliation: Universidade Federal do Rio Grande do Norte
name: Wouber Hérickson de Brito Vieira, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Universidade Federal do Rio Grande do Norte
name: Bento João Abreu, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: da Silva FS, de Melo FE, do Amaral MM, Caldas VV, Pinheiro IL, Abreu BJ, Vieira WH. Efficacy of simple integrated group rehabilitation program for patients with knee osteoarthritis: Single-blind randomized controlled trial. J Rehabil Res Dev. 2015;52(3):309-22. doi: 10.1682/JRRD.2014.08.0199.
Clinical trial NCT02788162: 18616 - Sun Protection Factor Assay
Official title: Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sunscreening Agent
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2016-06-02
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the Sun Protection Factor efficacy on human skin.


Eligibility criteria: Inclusion Criteria:

* Fitzpatrick Skin Type l, ll and/or lll for UVB testing. Fitzpatrick Skin Type ll, lll and/or lV for UVA testing.
* Male and female
* Aged between 18-70 years old.
* Good health as determined from the HRL SHF (Subject History Form)
* Signed and dated Informed Consent Form
* Signed and dated HIPAA (Health Insurance Portability and Accountability Act) form.
* An unambiguous MED (Minimal Erythema Dose ) or MPPD (Minimal Persistent Pigment Darkening Dose)

Exclusion Criteria:

* Subjects on test at any other research laboratory or clinic.
* Known allergy or sensitivity to sunscreens, cosmetics and toiletries, topical drugs and/or ultraviolet light.
* Pre-existing dermatologic conditions which have been diagnoses by a medical professional (e.g. psoriasis, eczema, etc.) which would interfere with this study.
* Pre-existing other medical conditions (e.g. adult asthma. diabetes).
* Treatment with antihistamines or corticosteroids within one week prior to initiation of the test.
* Treatment with antibiotics within two weeks prior to initiation of the test.
* Chronic medication which could affect the results of the study.
* Known pregnant or nursing women.

Primary outcomes:
measure: Minimal Erythema Dose (MED)
timeFrame: Up to 15 minutes
measure: Minimal Persistent Pigment Darkening Dose (MPPD)
timeFrame: Up to 15 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Union
country: United States
state: New Jersey
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT00851162: Using Mesenchymal Stem Cells to Fill Bone Void Defects in Patients With Benign Bone Lesions
Official title: Using Mesenchymal Stem Cells to Fill Bone Void Defects in Patients With Benign Bone Lesions
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
PHASE3
Conditions: Bone Neoplasms
Keywords: Bone defect
Benign bone lesions
Stem cells
Lead sponsor: Emory University
Sponsor class: OTHER
First posted: 2009-02-25
Enrollment: 0
Sex: ALL
Minimum age (years): 11
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether using mesenchymal stem cells will heal benign bone lesion defects faster than demineralized bone matrix

Detailed description: Orthobiologics have recently become a mainstay in treating bony defects whether related to trauma, tumor, or other various reconstructive entities.1 Historically, benign bone growths that were excised, would be filled with either cement, autograft bone, or allograft substances. More recently, other substances have been utilized. These substances carry any or all osteoinductive, osteoconductive, or osteogenic properties. Various materials have been used to fill bony voids specifically related to benign bone growths. Trinity™ by Blackstone Medical inc. is an allograft substance that has recently began utilization. The difference in Trinity compared to various other allografts is that it utilizes mesenchymal stem cells (MSC) along with an allograft carrier to incorporate and induce bone formation. Previously, in order for stem cells to be included in grafting, it would require bone marrow aspiration and the morbidity that is associated with iliac crest bone grafting.

Trinity MSC's are pre-immunodepleted and therefore, do not stimulate local T-cell proliferation but instead are activated to act as osteoblasts and stimulate bone formation. This local response, could accelerate healing, earlier weight-bearing, healing, and filing of bone voids in patients that have had excision of bony masses. In previous animal models, the use of MSC's have been shown to increase bone healing in critical sized defects.

Trinity is currently approved for FDA use in bone defects specifically within the spine or trauma. It has not been shown to have any significant adverse events over standard bone substitute products. We hypothesize benign bone lesions that undergo curettage and filling with Trinity will heal faster than bone lesions filled with basic bone grafting.

Eligibility criteria: Inclusion Criteria:

* Ages \> 11 years
* Benign bone lesion

Exclusion Criteria:

* Previous surgery

Primary outcomes:
measure: Time to fill bony defect
timeFrame: Two to 52 weeks
Secondary outcomes:
measure: Adverse reaction from bone graft
timeFrame: Immediately after surgery to one year
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Emory University
state: Georgia
Study officials:
affiliation: Emory University Department of Orthopaedics
name: Shervin Oskouei, MD
role: PRINCIPAL_INVESTIGATOR
References: